Newamsterdam Pharma Company N.V. ( (NAMS) ) has released its Q1 earnings. Here is a breakdown of the information Newamsterdam Pharma Company N.V. presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company based in the Netherlands, focusing on developing therapies for cardiometabolic diseases, with a primary emphasis on their CETP inhibitor, obicetrapib, aimed at lowering LDL-C levels in patients where current treatments are inadequate.